Form 4: Stoke Therapeutics Director Sells Shares

Stoke Therapeutics Director Adrian R. Krainer reported the sale of 33,243 shares of common stock at a weighted average price of $39.7366 per share.

Summary

• Adrian R. Krainer, a Director of Stoke Therapeutics, Inc. (STOK), reported the sale of 33,243 shares of common stock.
• The transaction occurred on March 10, 2026.
• The shares were sold at a weighted average price of $39.7366, with individual transactions ranging from $39.50 to $40.11 per share.
• Following this transaction, Krainer beneficially owns 283,302 shares of Stoke Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-determined, non-discretionary transaction, mitigating immediate negative sentiment.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• A director selling a significant number of shares (33,243) could be perceived negatively by investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this to some extent.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned via a 10b5-1 plan, are routinely monitored by investors for insights into management's perspective on future company performance. In the biotechnology sector, such sales are common for diversification or liquidity purposes, but the timing and volume are always scrutinized.

Comparison to Industry Standards

• Insider sales are a common occurrence across all industries, including biotechnology. For example, executives at companies like Moderna or Pfizer also utilize 10b5-1 plans for planned stock divestitures.
• The sale of 33,243 shares by a director, while notable, is not an unusually large volume compared to some insider transactions seen in larger cap biotech firms, but it represents a portion of the director's overall holdings in Stoke Therapeutics.

Related Party Transactions

• Adrian R. Krainer, a Director of Stoke Therapeutics, Inc., sold 33,243 shares of common stock, which constitutes a related party transaction as he is an insider.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though the 10b5-1 plan reduces the implication of immediate negative sentiment.

Key Dates

Recommendation

The transaction is a pre-planned insider sale, not indicative of new material information or a change in the company's fundamental outlook. While a sale by a director can sometimes raise questions, the 10b5-1 plan suggests a routine diversification or liquidity event. Therefore, existing investors should hold, and new investors should base decisions on broader company fundamentals rather than this single transaction.

Keywords

Stoke Therapeutics, STOK, Insider Sale, Form 4, Adrian R. Krainer, Director, Stock Transaction, Rule 10b5-1